Madrigal Secures Exclusive License from Pfizer for Ervogastat
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Should l Buy MDGL?
Source: Newsfilter
Madrigal Pharmaceuticals' stock has hit a 20-day low, dropping 3.25% amid broader market declines.
The company has secured an exclusive global license from Pfizer for ervogastat, a clinical-stage oral DGAT-2 inhibitor, with an upfront payment of $50 million. This agreement strengthens Madrigal's position in MASH therapies and follows promising results from a prior Phase 2 study where 72% of patients achieved at least a 30% reduction in liver fat. Despite this positive development, the stock's decline reflects ongoing market concerns, particularly after a recent downgrade by Wolfe Research, which has overshadowed the potential benefits of the new licensing agreement.
The implications of this licensing deal could be significant for Madrigal, as it enhances their treatment portfolio for MASH. However, the market's reaction indicates a cautious sentiment, suggesting that investors are weighing the potential of this new partnership against the backdrop of recent downgrades and overall market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDGL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDGL
Wall Street analysts forecast MDGL stock price to rise
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 438.730
Low
527.00
Averages
636.22
High
900.00
Current: 438.730
Low
527.00
Averages
636.22
High
900.00
About MDGL
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Undervalued Investment Opportunities: Axsome and Madrigal
- Axsome's Growth Potential: Axsome Therapeutics' stock has more than doubled over the past five years, primarily due to clinical and commercial progress with its leading candidate Auvelity, with new approvals and label expansions expected to significantly enhance financial performance and potentially lead to profitability in the next five years.
- Significant Revenue Increase: In 2025, Axsome's revenue surged by 66% to $638.5 million, while its net loss per share improved to $3.68 from $5.99 in 2024, indicating strong performance in large, underserved markets.
- Madrigal's FDA Approval: Madrigal Pharmaceuticals received FDA approval for Rezdiffra in 2024, the first drug indicated for metabolic dysfunction-associated steatohepatitis, generating $958.4 million in revenue last year, highlighting robust market demand.
- Huge Market Demand: Madrigal targets 315,000 patients, having treated about 36,250 so far, indicating significant market potential in the MASH area, with prospects for sustained financial growth and competitive returns in the future.
See More
Axsome and Madrigal's Market Potential
- Axsome's Growth Potential: Axsome Therapeutics' stock has more than doubled over the past five years, primarily due to clinical and commercial progress with its leading candidate Auvelity, which is expected to significantly improve financial performance through new approvals and label expansions over the next five years.
- Significant Revenue Increase: In 2025, Axsome's revenue surged by 66% to $638.5 million, and although the net loss per share was $3.68, it showed improvement compared to the $5.99 loss per share reported in 2024, indicating potential for profitability.
- Madrigal's Market Breakthrough: Madrigal Pharmaceuticals received FDA approval for Rezdiffra in 2024, the first drug indicated for metabolic dysfunction-associated steatohepatitis, generating $958.4 million in revenue last year solely from this product, highlighting strong market demand.
- Unmet Medical Needs: Madrigal has treated approximately 36,250 patients, targeting 315,000, indicating a significant unmet need in the metabolic dysfunction-associated steatohepatitis space, which is likely to drive continued financial growth.
See More
Madrigal (MDGL) Q4 2025 Earnings Call Transcript
See More
Baker Bros. Advisors Increases Stake in Kymera Therapeutics
- Stake Increase: Baker Bros. Advisors reported a purchase of 2,005,813 shares of Kymera Therapeutics in its February 17, 2026 SEC filing, representing an estimated trade value of $135.45 million, indicating strong confidence in the company.
- Market Value Growth: The fund's quarter-end position in Kymera Therapeutics increased by $297.15 million due to this purchase, reflecting the dual impact of trading activity and share price appreciation, further solidifying its market position.
- Stock Performance: As of February 17, 2026, Kymera's shares were priced at $84.84, marking a 130% increase over the past year, significantly outperforming the S&P 500 by 118.13 percentage points, showcasing its robust performance in the biotech sector.
- R&D Outlook: With approximately $1.6 billion in cash at the beginning of 2026, Kymera supports its leading oral immunology pipeline, which is expected to drive sustained growth for the company in the coming years.
See More
U.S. Markets Fell on Thursday; Klarna Group Reported Largest Loss
- U.S. Stock Market Performance: Stock indexes in the U.S. experienced a decline on Thursday, with the overall market falling by 0.54%.
- Specific Index Movements: The S&P 500 index decreased by 0.31%, while the Dow Jones Industrial Average dropped by 0.28%.
See More
Madrigal Pharmaceuticals Q4 2025 Earnings Call Highlights
- Significant Sales Performance: Madrigal Pharmaceuticals reported net sales of $321 million in Q4 2025, more than tripling from Q4 2024, with full-year net sales reaching $958.4 million, demonstrating strong market demand for Rezdiffra as a foundational therapy.
- Sustained Patient Growth: The number of patients on Rezdiffra exceeded 36,250 by the end of Q4 2025, up from over 29,500 in Q3, indicating the company's success in patient acquisition and market penetration.
- Increased R&D and Expenses: R&D expenses for Q4 2025 were $116.3 million, totaling $388.5 million for the year, primarily driven by upfront payments for new pipeline assets, which are expected to propel future product development and market expansion.
- Optimistic Future Outlook: CFO Dier anticipates robust net sales growth in 2026, despite an increase in gross-to-net impact into the high 30% range due to contracting, indicating the company’s strong growth potential in a competitive market.
See More
Undervalued Investment Opportunities: Axsome and Madrigal
- Axsome's Growth Potential: Axsome Therapeutics' stock has more than doubled over the past five years, primarily due to clinical and commercial progress with its leading candidate Auvelity, with new approvals and label expansions expected to significantly enhance financial performance and potentially lead to profitability in the next five years.
- Significant Revenue Increase: In 2025, Axsome's revenue surged by 66% to $638.5 million, while its net loss per share improved to $3.68 from $5.99 in 2024, indicating strong performance in large, underserved markets.
- Madrigal's FDA Approval: Madrigal Pharmaceuticals received FDA approval for Rezdiffra in 2024, the first drug indicated for metabolic dysfunction-associated steatohepatitis, generating $958.4 million in revenue last year, highlighting robust market demand.
- Huge Market Demand: Madrigal targets 315,000 patients, having treated about 36,250 so far, indicating significant market potential in the MASH area, with prospects for sustained financial growth and competitive returns in the future.
See More
Axsome and Madrigal's Market Potential
- Axsome's Growth Potential: Axsome Therapeutics' stock has more than doubled over the past five years, primarily due to clinical and commercial progress with its leading candidate Auvelity, which is expected to significantly improve financial performance through new approvals and label expansions over the next five years.
- Significant Revenue Increase: In 2025, Axsome's revenue surged by 66% to $638.5 million, and although the net loss per share was $3.68, it showed improvement compared to the $5.99 loss per share reported in 2024, indicating potential for profitability.
- Madrigal's Market Breakthrough: Madrigal Pharmaceuticals received FDA approval for Rezdiffra in 2024, the first drug indicated for metabolic dysfunction-associated steatohepatitis, generating $958.4 million in revenue last year solely from this product, highlighting strong market demand.
- Unmet Medical Needs: Madrigal has treated approximately 36,250 patients, targeting 315,000, indicating a significant unmet need in the metabolic dysfunction-associated steatohepatitis space, which is likely to drive continued financial growth.
See More
Madrigal (MDGL) Q4 2025 Earnings Call Transcript
See More
Baker Bros. Advisors Increases Stake in Kymera Therapeutics
- Stake Increase: Baker Bros. Advisors reported a purchase of 2,005,813 shares of Kymera Therapeutics in its February 17, 2026 SEC filing, representing an estimated trade value of $135.45 million, indicating strong confidence in the company.
- Market Value Growth: The fund's quarter-end position in Kymera Therapeutics increased by $297.15 million due to this purchase, reflecting the dual impact of trading activity and share price appreciation, further solidifying its market position.
- Stock Performance: As of February 17, 2026, Kymera's shares were priced at $84.84, marking a 130% increase over the past year, significantly outperforming the S&P 500 by 118.13 percentage points, showcasing its robust performance in the biotech sector.
- R&D Outlook: With approximately $1.6 billion in cash at the beginning of 2026, Kymera supports its leading oral immunology pipeline, which is expected to drive sustained growth for the company in the coming years.
See More
U.S. Markets Fell on Thursday; Klarna Group Reported Largest Loss
- U.S. Stock Market Performance: Stock indexes in the U.S. experienced a decline on Thursday, with the overall market falling by 0.54%.
- Specific Index Movements: The S&P 500 index decreased by 0.31%, while the Dow Jones Industrial Average dropped by 0.28%.
See More
Madrigal Pharmaceuticals Q4 2025 Earnings Call Highlights
- Significant Sales Performance: Madrigal Pharmaceuticals reported net sales of $321 million in Q4 2025, more than tripling from Q4 2024, with full-year net sales reaching $958.4 million, demonstrating strong market demand for Rezdiffra as a foundational therapy.
- Sustained Patient Growth: The number of patients on Rezdiffra exceeded 36,250 by the end of Q4 2025, up from over 29,500 in Q3, indicating the company's success in patient acquisition and market penetration.
- Increased R&D and Expenses: R&D expenses for Q4 2025 were $116.3 million, totaling $388.5 million for the year, primarily driven by upfront payments for new pipeline assets, which are expected to propel future product development and market expansion.
- Optimistic Future Outlook: CFO Dier anticipates robust net sales growth in 2026, despite an increase in gross-to-net impact into the high 30% range due to contracting, indicating the company’s strong growth potential in a competitive market.
See More
